Variation in Mycobacterium tuberculosis population structure in Iran: a systemic review and meta-analysis

Shima Hadifar 1,2, Abolfazl Fateh 1,2, Vahid Pourbakhordar 3, Seyed Davar Siadat 1,2, Shayan Mostafaei 4,5* and Farzam Vaziri 1,2*

Abstract

Background: Acquiring comprehensive insight into the dynamics of Mycobacterium tuberculosis (Mtb) population structure is an essential step to adopt effective tuberculosis (TB) control strategies and improve therapeutic methods and vaccines. Accordingly, we performed this systematic review and meta-analysis to determine the overall prevalence of Mtb genotypes/sublineages in Iran.

Methods: We carried out a comprehensive literature search using the international databases of MEDLINE and Scopus as well as Iranian databases. Articles published until April 2020 were selected based on the PRISMA flow diagram. The overall prevalence of the Mtb genotypes/sublineage in Iran was determined using the random effects or fixed effect model. The metafor R package and MedCalc software were employed for performing this meta-analysis.

Results: We identified 34 studies for inclusion in this study, containing 8329 clinical samples. Based on the pooled prevalence of the Mtb genotypes, NEW1 (21.94, 95% CI: 16.41–28.05%), CAS (19.21, 95% CI: 14.95–23.86%), EAI (12.95, 95% CI: 7.58–19.47%), and T (12.16, 95% CI: 9.18–15.50%) were characterized as the dominant circulating genotypes in Iran. West African (L 5/6), Cameroon, TUR and H37Rv were identified as genotypes with the lowest prevalence in Iran (< 2%). The highest pooled prevalence rates of multidrug-resistant strains were related to Beijing (2.52, 95% CI) and CAS (1.21, 95% CI).

Conclusions: This systematic review showed that Mtb populations are genetically diverse in Iran, and further studies are needed to gain a better insight into the national diversity of Mtb populations and their drug resistance pattern.

Keywords: Mycobacterium tuberculosis, Genotype, Diversity, Meta-analysis, Iran
Background
Tuberculosis (TB) remains the most lethal infectious disease with an estimated rate of 1.4 million deaths in 2018 [1]. Human-adapted Mycobacterium tuberculosis (MTBC), as a causative agent of TB infection, belong to eight phylogenetic branches with a phyleogeographic population structure [2, 3]. These lineages include Indo-Oceanic lineage (Lineage 1), East Asian (Lineage 2), Central Asian (Lineage 3), Euro-American (Lineage 4), Ethiopian (Lineage 7), known as Mycobacterium tuberculosis sensu stricto, West African 1 (Lineage 5) and West African 2 (Lineage 6), referred to as Mycobacterium africanaum and Lineage 8 (L8) which geographically restricted to the African Great Lakes region [2–4].

Different studies have shown that genomic differences among MTBC lineages or sublineages can affect the clinical and epidemiological characteristics of TB infection [5–8]. In recent decades, some Mycobacterium tuberculosis (Mtb) lineages/sublineages have attracted wide attention due to certain features such as transmission potential, pathogenic properties and association with drug resistance [9, 10]. Lineages 2 and 4 are widely distributed and seem to have a higher pathogenic power compared to geographically restricted lineages [2, 11, 12]. In West and South Asia, a sharp increase has been documented in the circulation of certain sublineages such as NEW-1 (Lineage 4) and CAS (Lineage 3) strains that are prone to emerging as resistant clones [13–15]. This growing increase seems be more important in Iran with the national average TB rate of 14 cases per 100,000 population, due to the influx of Afghan refugees and population growth [1]. Accordingly, acquiring comprehensive insight into the dynamics of Mtb population structure is an essential step to adopt effective TB control strategies and improve therapeutic methods and vaccines.

Therefore, the current systematic review and meta-analysis was conducted to determine (1) the overall prevalence of Mtb genotypes/sublineages and (2) to determine the dominant multidrug-resistant (MDR) Mtb genotypes in TB patients in Iran.

Methods
Study protocol
The meta-analysis was based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines for systematic reviews and meta-analyses [16]. The study protocol was registered in the PROSPERO database (CRD42020186561).

Search strategy and selection criteria
For evaluating the diversity of Mtb isolates in Iran, a comprehensive literature search was conducted using the international electronic databases of MEDLINE and Scopus as well as Iranian databases. English-language studies published until April 2020 were retrieved using the following keywords: “Mycobacterium tuberculosis”, “tuberculosis”, “molecular typing”, “genetic diversity”, “genotyping” and “Iran” combined with the Boolean operators “OR”, “AND” and “NOT” in the Title/Abstract/Keywords field. Additional keywords such as “lineage” combined with “Mycobacterium tuberculosis” were used to avoid missing any articles. Similar strategies using Persian keywords were used to find relevant Persian original articles in Iranian databases, such as Scientific Information Database (www.sid.ir), Irandoc (www.irandoc.ac.ir), Magiran (www.magiran.com), and Iranmedex (www.iranmedex.com).

The titles and abstracts of all the identified articles were reviewed for eligibility, then screening for relevant articles were performed by reviewing the full texts.

The inclusion criteria were: 1) studies reporting the prevalence of Mtb genotypes among TB patients, 2) studies presenting data from Iran irrespective of the publication year, and 3) studies used Spoligotyping, mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) typing and Whole-Genome Sequencing (WGS) methods for genotyping. The exclusion criteria, on the other hand, included:1) studies only presenting prevalence data on Mtb genotypes among drug-resistant Mtb isolates, 2) studies providing incomplete data, 3) studies published as meta-analyses and systematic reviews, 4) studies not in English or Persian, 5) studies limited to a single genotype, 6) studies that lacked genotyping data, and 7) studies that were not related to human TB molecular epidemiology. Data screening was performed by two reviewers independently.

Data extraction and quality assessment
Data from the studies meeting our inclusion criteria were extracted. We required the following data: first author’s name, year of publication, study area, molecular techniques, genotype, number of genotypes, total sample size, MDR genotype, sample type and nationality.

According to the items defined in the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist, we evaluated the methodological quality of the included studies using the pre-defined criteria presented in Table 1. This checklist consists of various methodological aspects, and a maximum quality evaluation score of 32 was considered and articles with scores below 18 were excluded from this study [51]. Data extraction and quality assessment were also carried out by two reviewers independently.

Statistical analysis
Pooled proportion and 95% CI were used to assess the prevalence of the genotypes in the pulmonary
| First author       | Location | Typing method | Year of publication | Genotypes                                           | Total of genotypes | MDR genotypes | Sample size | STROBE Score | Type of sample | Nationality                |
|--------------------|----------|---------------|---------------------|----------------------------------------------------|--------------------|---------------|-------------|---------------|----------------|---------------------------|
| Amirmozafari       | Tehran   | Spoligo       | 2006                | CAS- EAI-Beijing-T- Haarlem-MANU                   | CAS19- EAI31-Beijing14-T39-Haarlem75-MANU1-LAM1-West African1 | –               | 439         | 23            | PTB-EPTB         | Iranian - Afghan immigrants |
| Ramazanzadeh       | Tehran   | Spoligo       | 2006                | CAS- EAI-Beijing-T- Haarlem-West African - LAM    | CAS7- EAI27-Beijing12-T36-Haarlem65-West African1-LAM1 | –               | 346         | 26            | PTB-EPTB         | Iranian                   |
| Ramazanzadeh       | Tehran   | Spoligo       | 2006                | CAS- EAI-Beijing-T- Haarlem                        | CAS1- EAI4-Beijing5-T6-Haarlem20                          | –               | 93          | 27            | PTB-EPTB         | Afghan immigrants          |
| Masjedi            | Tehran   | IS6110-RFLP   | 2008                | CAS- EAI-Beijing-T- Haarlem-X                    | CAS38-EAI71-Beijing8-T44-Haarlem14-X1                      | Beijing2- Haarlem3 | 199         | 26            | PTB-EPTB         | Iranian                   |
| Masjedi            | Tehran   | IS6110-RFLP   | 2008                | CAS- EAI-Beijing-T- Haarlem-X                    | CAS12-EAI19-Beijing4-T3-Haarlem6-X11                     | Beijing1-T:1-Haarlem5 | 59          | 24            | PTB-EPTB         | Afghan immigrants          |
| Tajeddin           | Tehran   | Spoligo       | 2009                | CAS- EAI-Beijing-T- Haarlem-U                    | CAS118-EAI64-Beijing15-T16-Haarlem13-U12                  | CAS7-EAI8-Beijing6-T2-U2-Haarlem3                       | 238         | 28            | PTB             | Iranian                   |
| Ramazanzadeh       | Tehran   | Spoligo       | 2009                | CAS-Beijing-T-Haarlem-MANU-EAI-LAM-West African  | CAS18-Beijing14-T39-Haarlem75-MANU4-EAI31-LAM1-West African1 | –               | 523         | 30            | PTB-EPTB         | Iranian - Afghan immigrants |
| Rohani             | Mashhad  | Spoligo       | 2009                | CAS-NEW1-Beijing-T-Haarlem-MANU-URAL-EAST MED    | CAS6-NEW1.2-Beijing8-T2-Haarlem1-URAL1-EASTMED3          | Beijing3                      | 113         | 25            | PTB             | Iranian - Afghan immigrants |
| Ahmadi             | Tehran   | Spoligo       | 2009                | CAS- EAI-Beijing-T- Haarlem-U-Bovis              | CAS55- EAI39-Beijing6-T16- Haarlem52-U9-Bovis2            | –               | 179         | 24            | PTB             | Iranian                   |
| Ahmadi             | Tehran   | Spoligo       | 2009                | CAS- EAI-Beijing- Haarlem-U                      | CAS19- EAI16-Beijing7- Haarlem14-U-3                      | –               | 59          | 22            | PTB             | Afghan immigrants          |
| Jafarian           | Tehran   | 12 loci MIRU-VNTR /Spoligo | 2010                | CAS- NEW1-Haarlem-LAM-Uganda                   | CAS8- NEW1.6-Haarlem7-LAM2-Uganda2                        | 0                | 30          | 24            | PTB             | Iranian                   |
| Merza              | Tehran   | Spoligo       | 2010                | CAS- Bejing- EAI- Haarlem-T-X                    | CAS169- Bejing: 11- EAI212- Haarlem:41, T34-X16          | –               | 981         | 30            | PTB             | Iranian                   |
| Merza              | Tehran   | Spoligo       | 2010                | CAS- Beijing- EAI- Haarlem-T-X                    | CAS176- Bejing: 76- EAI174- Haarlem:31, T67-X10        | –               | 634         | 30            | PTB             | Afghan immigrants          |
| Merza              | Tehran   | Spoligo       | 2010                | CAS- Beijin- EAI- Haarlem-T-X                    | CAS12- Beijin: 1- EAI15- Haarlem3-T23-X2                  | –               | 93          | 22            | EPTB            | Iranian                   |
| Merza              | Tehran   | Spoligo       | 2010                | CAS- Beijin- EAI- Haarlem-T-X                    | CAS7- Beijin: 4- EAI5- Haarlem2-T3-                      | –               | 34          | 23            | EPTB            | Afghan immigrants          |
Table 1 Characteristics of 34 included studies in this meta-analysis (Continued)

| First author | Location | Typing method          | Year of publication | Genotypes | Total of genotypes | MDR genotypes | Sample size | STROBE Score | Type of sample | Nationality               |
|--------------|----------|------------------------|---------------------|-----------|--------------------|---------------|-------------|--------------|----------------|--------------------------|
| Asgharzadeh  [26] | Azarbaijan | IS6110-RFLP /12 loci MIRU-VNTR | 2011 | T-X | X:1 | – | 154 | 26 | PTB-EPTB | Iranian immigrants |
| Jafarian [27] | Tehran | 12 loci MIRU-VNTR | 2011 | CAS-NEW1-Beijing-Haarlem-EAI-LAM-Uganda-H37Rv-Bovis | CAS49-NEW1:16-Beijing:14-Haarlem:3-EAI:1-LAM:14-Uganda:28-H37Rv:5-Bovis:10 | – | 140 | 26 | PTB | Iranian - Afghan immigrants |
| Zaker Bostanabad [28] | Tehran | Spoligo | 2011 | CAS-Beijing-EAI-Haarlem-T-U | CAS18-Beijing:38-U8-EAI34-Haarlem:41-T:10 | CAS2-Beijing:1-EAI:3-U:1 | 149 | 25 | PTB | Iranian |
| Mozafari [29] | Tehran | 12/15 loci MIRU-VNTR /spoligo | 2012 | CAS-NEW1-Beijing-Haarlem-LAM-URAL-Uganda-X5-Cameroon-Bovis | CAS22-NEW1:25-Beijing:20-Haarlem:2-LAM5-URAL3-Uganda:9-X:1-52-Cameroon:1-Bovis:1 | Beijing:7 | 105 | 27 | PTB-EPTB | Iranian |
| Haeili [30] | 5 provinces | Spoligo | 2013 | CAS-NEW1-Beijing-Haarlem-T-MANU-LAM-EAI-U-H37Rv | CAS70-NEW1:110-Beijing:3-T:53-Haarlem:3-MANU22-LAM18-EAI4-U3-H37Rv2 | CAS1-NEW1:15-Beijing:3 | 291 | 29 | PTB-EPTB | Iranian |
| Torkaman [31] | Tehran | 15 loci MIRU-VNTR /spoligo | 2014 | CAS-NEW1-Beijing-Haarlem-URAL-T-MANU-Bovis | CAS15-NEW1:14-Beijing6-Haarlem3-T6-MANU8-URAL2-Bovis:3 | – | 73 | 26 | PTB | Iranian |
| Torkaman [31] | Tehran | 15 loci MIRU-VNTR /spoligo | 2014 | CAS-NEW1-Beijing-Haarlem | CAS5-NEW1:7-Beijing:5-Haarlem:1 | – | 29 | 24 | PTB | Afghan immigrants |
| Velayati [32] | 21 provinces | Spoligo | 2014 | CAS-Beijing-Haarlem-T-MANU-LAM-EAI-U-X-Bovis | CAS471-EAI3-Beijing:101-T:195-Haarlem:326-MANU25-LAM15-U17-Bovis:10-X:2 | – | 1242 | 31 | PTB | Iranian-immigrants |
| Varahram [33] | Tehran | Spoligo | 2014 | CAS-Beijing-Haarlem-T-MANU-LAM-EAI-U | CAS23-EAI42-Beijing:14-T:11-Haarlem:31-MANU9-LAM3-U7 | CAS1-1-T:1-EAI:5-Beijing:10-Haarlem:2-MANU2-LAM1-U1 | 151 | 27 | PTB | Iranian - Afghan immigrants |
| Sharifpour [34] | Tehran | Spoligo | 2014 | CAS-Beijing-Haarlem-T-MANU-LAM-EAI-U | CAS37-Beijing:11-Haarlem:72-T:18 | CAS3-T3-Beijing:4-Haarlem:3 | 190 | 25 | PTB | Iranian |
| Haeili [35] | IRAN | Spoligo | 2015 | CAS-NEW1-T-MANU-LAM | CAS60-NEW1:86-T46-MANU19-LAM:15 | – | 251 | 25 | PTB | Iranian |
| Sharifpour [36] | Tehran | RD Typing / Spoligo | 2016 | CAS-Beijing-Haarlem-T-MANU-LAM-EAI-U | CAS54-Beijing:28-Haarlem:85-T27 | – | 250 | 26 | PTB | Iranian |
| Feyisa [37] | Tehran | IS6110-RFLP /spoligo | 2016 | CAS-NEW1-Beijing-Haarlem-EAI-MANU-LAM-H37Rv | CAS18-NEW1:15-Beijing1-Haarlem1-T7-EAI4-MANU3-LAM1-H37Rv1 | – | 60 | 22 | PTB | Iranian |
| Feyisa [37] | Tehran | IS6110-RFLP /spoligo | 2016 | NEW1-T-EAI | NEW1:T-2-EAI:1 | – | 10 | 20 | PTB | Afghan immigrants |
| Zamani [38] | Hormozgan | IS610 loci MIRU-VNTR /spoligo | 2016 | CAS-Beijing-NEW1-T-Haarlem-LAM-MANU-EAI | CAS7-Beijing1-NEW1:2-Haarlem1-LAM9-MANU3-EAI1-T5 | T2-MANU1 | 38 | 25 | PTB | Iranian |
Table 1 Characteristics of 34 included studies in this meta-analysis (Continued)

| First author          | Location | Typing method | Year of publication | Genotypes | Total of genotypes | MDR genotypes | Sample size | STROBE Score | Type of sample | Nationality |
|-----------------------|----------|---------------|---------------------|------------|-------------------|---------------|-------------|---------------|----------------|-------------|
| Riyahi Zaniani        | Isfahan  | 15 loci MIRU-VNTR | 2017               | CAS-NEW1-Beijing-URAL-LAM-S-X-EAI | CAS10-NEW1:9-Beijing:9-URAL2-LAM3-S:3-X:1-EAI | –            | 38          | 24            | PTB            | Iranian      |
| Riyahi Zaniani        | Isfahan  | 15 loci MIRU-VNTR | 2017               | CAS-NEW1-Beijing-URAL-LAM-S-X-EAI | CAS4-NEW1:3-Beijing:3-5:1 | –            | 11          | 23            | PTB            | Afghan immigrants |
| Ravansalar            | Khorasan | 12 loci MIRU-VNTR/Spoligo | 2017       | CAS-NEW1-Beijing-T-Haarlem-MANU-U | CAS19-Beijing:9-T3-Haarlem:67-MANU:1-U:5 | Beijing2 | 140         | 25            | PTB            | Iranian      |
| Mansoori              | Golestan | 24 loci MIRU-VNTR | 2018               | CAS-NEW1-Beijing-URAL-Haarlem-TUR | CAS31-NEW1:45-Beijing:18-URAL4-TUR2-Haarlem2 | 0           | 156         | 25            | PTB            | Iranian      |
| Azimi                 | Tehran   | 15 loci MIRU-VNTR | 2018               | CAS-NEW1-WestAfrican-Bovis-H37Rv | CAS1-NEW1:18-WestAfrican:1-Bovis:1-H37Rv:1 | –            | 80          | 24            | PTB            | Iranian      |
| Kargarpour            | Tehran   | Spoligo        | 2018               | CAS-NEW1-T-MANU | CAS2-NEW1:3-T1-MANU5 | –            | 14          | 25            | PTB-EPTB       | Iranian      |
| Kochkaksaraei         | Golestan | 15 loci MIRU-VNTR | 2019               | CAS-NEW1-Beijing-URAL-Haarlem-TUR-Cameroon | CAS15-NEW1:36-Beijing:22-URAL3-TUR1-Cameroon4 | 0           | 162         | 28            | PTB-EPTB       | Iranian      |
| Hadifar               | Tehran   | 24 loci MIRU-VNTR/Spoligo | 2019       | CAS-NEW1-Beijing-URAL-T-Haarlem-EASTMED | CAS25-NEW1:21-Beijing:10-URAL4-T2-Haarlem2-EASTMED4 | CAS1-NEW1:1-Beijing:5-T1 | 84          | 27            | PTB            | Iranian      |
| Hadifar               | Tehran   | 24 loci MIRU-VNTR/Spoligo | 2019       | CAS-NEW1-Beijing-URAL-T-Haarlem-EASTMED | CAS21-NEW1:28-Beijing:5-URAL6-T22-Haarlem2-EASTMED1-U:2 | CAS1-NEW1:1 | 88          | 28            | EPTB           | Iranian      |
| Afsahi-Gharamaleki     | Tabriz   | 15 loci MIRU-VNTR | 2019               | CAS-NEW1-Beijing-Uganda-LAM-TUR-Cameroon-Bovis-H37Rv | CAS1-NEW1:30-Beijing:4-Uganda:18-LAM1-TUR2-Cameroon:1-Bovis3-H37Rv1 | –           | 91          | 27            | PTB            | Iranian      |
| Hadifar               | Tehran   | 24 loci MIRU-VNTR/Spoligo | 2019       | CAS-NEW1-Beijing | CAS95-NEW1:80-Beijing42 | –            | 217         | 29            | PTB            | Iranian      |
| Vaziri                | Tehran   | WGS            | 2019               | CAS-NEW1-Beijing-URAL-T-H37Rv | CAS7-NEW1:8-Beijing:14-URAL2-T4-TUR1-H37Rv:1 | Beijing14 | 38          | 25            | PTB            | Iranian      |
| Kargarpour            | Tehran   | 24 loci MIRU-VNTR | 2019               | CAS-NEW1-Beijing-Uganda | CAS5-NEW1:2-Beijing:2-Haarlem1-Uganda:1 | –            | 12          | 26            | PTB            | Iranian      |
| Kargarpour            | Tehran   | 24 loci MIRU-VNTR | 2020               | CAS-NEW1-Beijing-Uganda | CAS9-NEW1:4-Beijing5-Haarlem1-Uganda:1 | 0           | 45          | 28            | PTB            | Iranian      |

PTB Pulmonary Tuberculosis, EPTB Extrapulmonary Tuberculosis, WGS Whole-Genome Sequencing, MDR Multidrug resistant
tuberculosis (PTB) and extrapulmonary tuberculosis (EPTB) samples. Generalized linear mixed model with random intercept logistic regression model was used for assessing pooled prevalence [52]. The heterogeneity of prevalence between the included studies was tested and quantified by using Cochran’s Q test and I² index, respectively [53]. Clopper-Pearson was run for evaluating pooled proportion and confidence interval in the individual studies. Also, continuity correction of 0.5 was considered in studies with zero cell frequencies [54]. The pooled proportion, as an overall prevalence of the genotypes, was derived by the random effects model because of significant heterogeneity between the individual studies. Publication bias was tested by Egger’s linear regression test and Begg’s test (P< 0.05 was set as the significance level for publication bias) [55]. All the statistical analyses were performed by using the metafor R package and MedCalc software.

Results

Search results and studies’ characteristics

A total of 316 articles were identified by the primary search strategy, of which 34 articles met the eligibility criteria and were included in this study (Fig. 1). The selected studies included 8329 clinical samples. Most of the studies were conducted in Tehran (capital of Iran). Publication year of these studies ranged from 2006 to 2020. Spoligotyping and MIRU-VNTR typing were identified as the most common methods of genotyping.

Quality assessment

Based on the scores of the STROBE checklist, the highest and lowest scores were related to the studies of Velayati et al. (2014) and Feyisa et al. (2016), respectively. The mean score of STROBE tool was 25.72 (SD = 2.42, range: 20–31) (Table 1).

Pooled prevalence of MTBC genotypes in the PTB and EPTB samples

Results of the random or fixed effects meta-analysis are summarized in Table 2. M. bovis as a member of the animal-adapted MTBC accounted for only 3.29% of the studied strains and Mtb sensu stricto (Lineages1–4) comprised the largest proportion of the studied strains. Based on the pooled prevalence of the Mtb genotypes in the PTB and EPTB samples, NEW1 (21.94, 95% CI: 16.41–28.05%), CAS (19.21, 95% CI: 14.95–23.86%), EAI (12.95, 95% CI: 7.58–19.47%), and T (12.16, 95% CI: 7.58–19.47%) were the most prevalent genotypes.
9.18–15.50%]) were found to be the dominant circulating genotypes in Iran. West African (L 5/6), Cameroon, TUR and H37Rv (parts of the Euro-American superlineage [L4]) were identified as genotypes with the lowest prevalence in Iran (< 2%). The forest plot of some of the genotypes (i.e., Beijing, CAS, and EAI) are shown in Fig. 2. In addition, the highest pooled prevalence of MDR strains was found in Beijing (2.52, 95% CI) and CAS (1.21, 95% CI) genotypes (Table 2).

**Publication bias**
We observed significant heterogeneity across the studies based on the I² index with a few exceptions (Table 2). However, publication bias was not significant based on the results of Egger's linear regression test and Begg's test.

**Discussion**
Based on the pooled data investigated, all MTBC lineages, except lineage 7 and 8, were found in Iran, which reflects the presence of high diversity in MTBC strains. Phylogeographical population structure of the MTBC stems from the interplay between different factors such as human migration, geography, genetic drift and host-pathogen interaction [4, 5, 56]. Iran is the main host country for Afghan refugees, but the main factor contributing to formation of MTBC lineages phylogeography in Iran has not been identified.

Study of global variation in MTBC strains showed that the prevalence of lineages 2, 3 and 4 strains may be increasing in West Asia, while the prevalence of lineage 1 is declining [15]. The summary of Mtb strains diversity in Iran, based on families/sublineage, showed that NEW1(L4) (21.94, 95% CI: 16.41–28.05%), CAS (L3) (19.21, 95% CI: 14.95–23.86%), EAI(L1) (12.95, 95% CI: 7.58–19.47%), and T (L4) (12.16, 95% CI: 9.18–15.50%) were the dominant circulating Mtb genotypes. EAI (L1) and CAS (L3) are mainly confined to the areas around the Indian Ocean [11]. Movement of strains with people from these regions may explain the presence of these genotypes in Iran. Besides, appearing CAS as a one of the prevalent Mtb subpopulations in Iran may reflect the pathogenic properties of this genotype.

In a recent study, the global proportion of MDR in CAS population was estimated at 30.63% [57]. In our study, based on the pooled prevalence of MDR genotype, CAS was found (1.21%) as a one of the dominant genotypes. This finding reflects the needs for more understanding and monitoring of this subpopulation.

**Table 2** Pooled prevalence of MTBC genotypes in each studied genotype in PTB and EPTB samples

| Lineage | Genotype (n), Pooled prevalence of MDR% | Pooled prevalence of genotype (n), Prevalence% (95% CI)% | Heterogeneity (Q, I²%) | Publication bias | Publication bias |
|---------|----------------------------------------|----------------------------------------------------------|------------------------|-----------------|-----------------|
| L1      | EAI (16), 1.17% (799), 12.95% (7.58–19.47)% | 935, 97.75% < 0.001 0.061 0.192 |
|         | MANU (3), 0.74% (116), 5.41% (3.03–8.43)% | 105, 89.58% < 0.001 0.06 0.17 |
| L2      | Beijing (52), 2.52% (481), 8.06% (5.96–10.44)% | 305, 90.52% < 0.001 0.14 0.27 |
| L3      | CAS (23), 1.21% (1761), 19.21% (14.95–23.86)% | 1016, 95.97% < 0.001 0.11 0.16 |
| L4      | NEW1 (7), 0.8% (568), 21.94% (16.41–28.05)% | 263, 90.89 < 0.001 0.09 0.31 |
| T       | Haarlem (13), 0.67% (989), 10.38% (6.62–14.87)% | 909, 96.59% < 0.001 0.054 0.116 |
| Uganda  | 0% (60), 9.04% (3.06–17.74)% | 53, 88.87% < 0.001 0.24 0.64 |
| S       | 0% (19), 6.24% (3.83–9.53)% | 6, 53.57% 0.091 0.415 0.817 |
| LAM     | 0% (89), 3.59% (1.85–5.86)% | 119, 89.08% < 0.001 0.052 0.095 |
| URAL    | 0% (27), 3.39% (2.28–4.82)% | 849, 5.38% 0.386 0.612 0.768 |
| EASTMED | 0% (8), 3.12% (1.43–5.84)% | 2, 0% 0.393 0.78 0.81 |
| X       | 0% (46), 2.03% (0.88–3.64)% | 55, 83.76% < 0.001 0.153 0.319 |
| H37Rv   | 0% (11), 1.78% (0.94–3.05)% | 5, 1.99% 0.403 0.419 0.778 |
| TUR     | 0% (6), 1.64% (0.68–3.29)% | 191, 0% 0.59 0.419 0.654 |
| Cameroon| 0% (7), 1.64% (0.73–3.15)% | 161, 0% 0.656 0.69 0.78 |
| L5/6    | West African 0% (4), 0.38% (0.13–0.87)% | 19, 0% 0.586 0.513 0.813 |
| Bovis   | 0% (45), 3.29% (1.31–6.13)% | 45, 84.73% < 0.001 0.112 0.278 |
| U       | 0% (66), 3.55% (2.13–5.31)% | 28, 72.14% < 0.001 0.09 0.26 |

Hadifar et al. BMC Infectious Diseases (2021) 21:2
Fig. 2 Forest plots displaying the prevalence of different *M. tb* genotypes in the studied geographical region.
prevalence of MDR strains was found in the Beijing (2.52%) genotype. This result is consistent with the previously published reports about the prevalence of Beijing among MDR-TB isolates in Iran [58]. The low prevalence of Beijing genotype compared to other genotypes in Iran may be explained by the prevalent Beijing sublineage, affecting its pathobiological properties and epidemiological dynamics. Further studies are warranted to identify the distribution pattern of the Beijing sublineages in Iran, which can improve the management of their infection.

The dominance of NEW1 as a specialist sublineage of Euro-American lineage (L4) in Iran was not unexpected. Some evidence has shown that Iran is the probable origin of this family/sublineage, which may reflect ecological adaption in this subpopulation [59]. It is noteworthy that NEW1 genotype is prone to MDR [13]. The pooled prevalence of MDR in NEW1 was 0.8% (95% CI). However, the results of overall MDR estimation may be less representative of the target population, as in the some of the included studies in our analysis; drug susceptibility testing was not reported based on the identified genotype, which may lead to variation in the final results. Other sublineages of lineage 4 such as T, Haarlem, Uganda and S in varying proportions were also observed. This distribution pattern in the subtypes of lineage 4 in Iran may be explained by the effect of human migration and genetic and phenotypic characteristics of each sublineage.

In addition, we observed that lineage 5/6 subtype had the lowest prevalence in our geographical region. Based on the fact that these strains are geographically restricted [2], we can only speculate human migration as the determinant of this distribution. A limitation of this study is that most of the included studies were conducted in Tehran (Capital of Iran). Thus, our finding may not be completely representative of the overall prevalence of different Mtb populations in Iran. In addition, the most of the included studies were based on Spoligotyping and MIRU-VNTR typing methods while WGS provides a superior resolution compared with these PCR-based genotyping methods to identification of diversity in Mtb strains.

Conclusions
In summary, this systematic review showed that Mtb population are genetically diverse in Iran and the NEW1 (L4) and West African (L5/6) genotypes had the highest and lowest pooled prevalence rates, respectively. This type of evidence can contribute to better clinical and epidemiological management of Mtb infections. Also, there is a need for further in-depth studies to gain a deeper insight into the national diversity of Mtb populations and their drug resistance pattern.
8. Sarkar R, Lenders L, Wilkinson KA, Wilkinson RJ, Nicol MP. Modern lineages of mycobacterium tuberculosis exhibit lineage-specific patterns of growth and cytokine induction in human monocyte-derived macrophages. PLOS ONE. 2012;7(8):e43170.

9. Hanekom M, van Pittius NG, McEvoy C, Victor T, Van Helden P, Warren R. Mycobacterium tuberculosis Beijing genotype: a template for future success. Tuberculosis. 2011;91(6):510–23.

10. Brynnildsrud OB, Pepperrill CS, Sufyri P, Grandjean L, Monteserini J, Debeb N, et al. Global expansion of mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation. Sci Adv. 2018;4(10):eaat5869.

11. Coscolla M. Biological and epidemiological consequences of MTBC diversity. In: Gagneux S, editor. Strain variation in the Mycobacterium tuberculosis complex: its role in biology, epidemiology and control. Cham: Springer International Publishing; 2017. p. 95–116.

12. Stucki D, Bittes D, Jeelji L, Coscolla M, Liu Q, Trauner A, et al. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages. Nat Genet. 2016;48(12):1535–43.

13. Mokrousov I. Emerging resistant clone of mycobacterium tuberculosis in West Asia. Lancet Infect Dis. 2016;16(12):1226–7.

14. Yasmin M, Gomgnimbou MK, Siddiqui RT, Refeger G, Sola C. Multi-drug resistant mycobacterium tuberculosis complex genetic diversity and clues on recent transmission in Punjab, Pakistan. Infect Genet Evol. 2014;27:7–6.

15. Wiens KE, Woyczynski LP, Ledesma JR, Ross JM, Zenteno-Cuevas R, Goodridge A, et al. Global variation in bacterial strains that cause tuberculosis disease: a systematic review and meta-analysis. BMC Med. 2018;16(1):16.

16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

17. Amirmozafari N, Ramazanzadeh R, Farnia P, Ghazi F. The frequency of Beijing genotype of mycobacterium tuberculosis isolated from tuberculosis patients. Razi J Med Sci. 2006;16(32):27–3.

18. Ramazanzadeh R, Amirmozafari N, Farnia P, Ghazi F. Genotyping of mycobacterium tuberculosis isolates from TB patients with spoligotyping. Sci J Kurdestan Univ Med Sci. 2006;11(1):50–9.

19. Masjedi MR, Varahram M, Mirsalehi M, Ahmadi M, Khazampour M, Tabarsi P, et al. The recent-transmission of mycobacterium tuberculosis strains among Iranian and afghan relapse cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infect Dis. 2008;8(1):109.

20. Tajeddin E, Farnia P, Kargar M, Noroozi J, Ahmadi M, Kazempour M, et al. Identification of mycobacterium tuberculosis Beijing genotype using three different molecular methods. Koomesh. 2009;11(1):7–14.

21. Ramazanzadeh R, Farnia P, Amirmozafari N. Characterization of mycobacterium tuberculosis complex isolated from iranian and afghani patients by spoligotyping method. Braz J Microbiol. 2009;40(2):314–20.

22. Rohani M, Farnia P, Nasab MN, Monirri R, Torfeh M, Amiri M. Beijing genotype and other predominant mycobacterium tuberculosis spoligotypes observed in Mashhad city, Iran. Indian J Med Microbiol. 2009;27(4):306.

23. Ahmadi M, Farnia P, Tajeddin E, Tabarsi P, Baghaei P, Masjedi M, et al. Mycobacterium tuberculosis complex strains identification with spoligotyping method in patients attending to Masih Daneshvari hospital. J Adv Med Biomed Res. 2009;17(6):23–32.

24. Jafarian M, Aghali-Merza M, Farnia P, Ahmadi M, Masjedi MR, Velayati AA. Synchronous comparison of mycobacterium tuberculosis epidemiology and colonial migration. Int J Tuberc Lung Dis. 2009;13(9):1168.

25. Merza MA, Farnia P, Salih AM, Masjedi MR, Velayati AA. The most problematic issue in the region with high prevalence of polyclonal mycobacterium tuberculosis isolates from five provinces of Iran. Microbiol Res. 2013;168(6):988–96.

26. Torkaman ARA, Nasiri MJ, Fahlenia P, Shohosseiny MH, Mozaﬁ M, Velayati AA. Estimation of recent transmission of mycobacterium tuberculosis strains among iranian and afghan immigrants: a cluster-based study. J Clin Diagn Res. 2014;8(6):OC05.

27. Velayati AA, Farnia P, Mozaﬁ M, Sheikholeslami MF, Karahрудی MA, Tabarsi P, et al. High prevalence of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. Am J Trop Med Hyg. 2014;90(1):199–105.

28. Varahram M, Farnia P, Nasiri MJ, Karahрудی MA, Dizajie MK, Velayati AA. Association of Mycobacterium tuberculosis lineages with IFN-γ and TNF-α gene polymorphisms among pulmonary tuberculosis patient. Mediterranean J Hemotol Infect Dis. 2014;6(1):e2014015–e.

29. Sharifipour E, Nasiri M, Farnia P, Mozaﬁ M, Irani S. Evaluation of molecular diversity of mycobacterium tuberculosis strains by polymorphisms in RD regions. J Mycobact. Dis. 2014;14(3):1061–1068.

30. Haelli M, Darban-Sarokhalil D, Fooladi AT, Zamani S, Zahednamazi F, Kardan J, et al. Genotyping and drug susceptibility testing of mycobacterium tuberculosis strains isolated from Iran. Int J Mycobacteriol. 2015;4:122.

31. Sharifipour E, Farnia P, Mozaﬁ M, Irani S, Velayati AA. Deletion of region of difference 181 in mycobacterium tuberculosis strains. Int J Mycobacteriol. 2016;5:5238–9.

32. Feyisa SG, Haelli M, Zahednamazi F, Mosavari N, Taheri MM, Hamzehloog H, et al. Molecular characterization of mycobacterium tuberculosis isolates from Tehran, Iran by restriction fragment length polymorphism analysis and spoligotyping. J Microbiol. 2016;24(3):204–10.

33. Zamani S, Haelli M, Nasiri MJ, Imami Fooladi AA, Javadpour S, Feizabadi MM. Genotyping of mycobacterium tuberculosis isolates from Hormozgan Province of Iran based on 15-locus MIRU-VNTR and spoligotyping. Int J Bacteriol. 2016;2016:7146470.

34. Zaniani FR, Moghim S, Milhendi H, Safaei HG, Fazeli H, Salehi M, et al. Genetic lineages of mycobacterium tuberculosis isolates in Isfahan, Iran. Curr Microbiol. 2017;74(1):14–21.

35. Ravansalar H, Tadayon K, Mosanav N, Denakhsh M, Ghazvini K. Genetic diversity of mycobacterium tuberculosis complex isolated from patients in the northeast of Iran by MIRU-VNTR and spoligotyping. Jundishapur J Microbiol. 2017;10(4):e93568.

36. Mansoori N, Yaseni M, Vaziri F, Douraghi M. Genetic diversity of mycobacterium tuberculosis complex isolates circulating in an area with high tuberculosis incidence: using 24-locus MIRU-VNTR method. Tuberculosis. 2018;112:89–97.

37. Azimi T, Nasiri MJ, Zamani S, Hashemi A, Goudarzi H, Fooladi AA, et al. High genetic diversity among mycobacterium tuberculosis strains in Tehran, Iran. J Clin Tubercul Mycobacteriol Dis. 2018;11:1–6.

38. Kamaloki MK, Kianipour S, Hadﬁr S, Ghajvand H, Farmanfarmaei G, Fateh A, et al. Challenge in direct Spoligotyping of mycobacterium tuberculosis: a problematic issue in the region with high prevalence of polyclonal infections. BMC Res Notes. 2018;11(1):486.

39. Babai Khojkisaraei M, Kaboosi H, Ghareim A. Genetic variation of the mycobacterium tuberculosis in north of Iran; the Golestan Province. Iran Red Crescent Med J. 2019;21(8):e91553.

40. Hadifar S, Shamliali L, Kamaloki MK, Mostafaei S, Kianipour S, Mansoori N, et al. Genetic diversity of mycobacterium tuberculosis isolates causing pulmonary and extrapulmonary tuberculosis in the capital of Iran. Mol Phylogenet Evol. 2019;132:46–52.

41. Afagh GA, Moaddab SR, Darbouy M, Ansarian K, Hafizan S. Genotypic diversity of resistant mycobacterium tuberculosis strains isolated from tuberculosis patients in East Azerbaijan center by MIRU-VNTR. J Microbiol World. 2019;13(4):320–31.

42. Hadifar S, Kamaloki MK, Fateh A, Sadat SD, Vaziri F. Enhancing the differentiation of specific genotypes in mycobacterium tuberculosis population. Sci Rep. 2019;9(1):1–9.

43. Vaziri F, Kohl TA, Ghajvand H, Kargarpour Kamaloki M, Merker M, Hadifar S, et al. Genetic diversity of multi- and extensively drug-resistant
mycobacterium tuberculosis isolates in the Capital of Iran, revealed by whole-genome sequencing. J Clin Microbiol. 2019;57(1):e01477–18.
49. Kargarpour Kamakoli M, Hadifar S, Khanipour S, Farmanfarmaei G, Fateh A, Siadat SD, et al. Comparison of MIRU-VNTR genotyping between old and fresh clinical samples in tuberculosis. Infect Dis. 2019;51(9):659–67.
50. Kamakoli MK, Farmanfarmaei G, Masoumi M, Khanipour S, Ghanizadeh S, Sola C, et al. Prediction of the hidden genotype of mixed infection strains in Iranian tuberculosis patients. Int J Infect Dis. 2020;95:22–7.
51. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–7.
52. Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29(29):3046–67.
53. Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I² index? Psychol Methods. 2006;11(2):193.
54. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.
55. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Brmj. 1997;315(7109):629–34.
56. Hershberg R, Lipatov M, Small PM, Sheffer H, Niemann S, Homolka S, et al. High functional diversity in mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 2008;6(12):e311.
57. Couvin D, Reynaud Y, Rastogi N. Two tales: worldwide distribution of central Asian (CAS) versus ancestral east-African Indian (EAI) lineages of mycobacterium tuberculosis underlines a remarkable cleavage for phylogeographical, epidemiological and demographical characteristics. PLoS One. 2019;14(7):e0219706.
58. Tarashi S, Fateh A, Jammani FR, Siadat SD, Vaziri F. Prevalence of Beijing and Haarlem genotypes among multidrug-resistant mycobacterium tuberculosis in Iran: systematic review and meta-analysis. Tuberculosis. 2017;107:31–7.
59. Mokrousov I, Shitikov E, Skiba Y, Kolchenko S, Chemyaeva E, Vyazovaya A. Emerging peak on the phylogeographic landscape of mycobacterium tuberculosis in West Asia: definitely smoke, likely fire. Mol Phylogenet Evol. 2017;116:202–12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.